Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
CRSP
STRONG SELLCRISPR Therapeutics AG · Healthcare · Switzerland · $4.6B · Avg Vol: $83M/d
COMPANY DESCRIPTION
CRISPR Therapeutics AG is a leading gene editing company leveraging its proprietary CRISPR/Cas9 technology to develop transformative gene-based medicines for serious genetic diseases and cancers. As a pioneer in the field, it holds foundational intellectual property and has brought the first CRISPR-based gene therapy, Casgevy, to market, establishing a significant early competitive advantage.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.4M | 370.0M | 35.0M | 0 | 796.0% | — | 42.2M | 162.8M | 66.9% |
| EPS | -8.36 | -1.94 | -4.34 | -6.47 | — | -6.07 | -4.86 | -3.89 | — |
| Shares | 78.5M | 80.0M | 85.7M | 95.9M | +22.1% | 98.5M | — | — | — |
| Debt | 244.0M | 238.6M | 223.7M | 206.7M | -5.4% | 787.6M | — | — | — |
| Equity | 1.9B | 1.9B | 1.9B | 1.9B | 0.8% | — | — | — | — |
| Op CF | -495.7M | -260.4M | -142.8M | -345.0M | — | -400.0M | — | — | — |
| Inv CF | -258.7M | 374.6M | -280.5M | -31.8M | — | — | — | — | — |
| Fin CF | 38.6M | 62.7M | 332.0M | 426.0M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of CRSP are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| CRSP | CRISPR Therapeutics AG(you) | $4.6B | 14 | STRONG SELL |
| MLTX | MoonLake Immunotherapeutics | $1.6B | 18 | STRONG SELL |
| PHVS | Pharvaris N.V. | $2.4B | 26 | SELL |
| IDIA.SW | Idorsia Ltd | $2.2B | 33 | SELL |
| BANB.SW | Bachem Holding AG | $6.7B | 52 | HOLD |
| OCS | Oculis Holding AG | $672M | 7 | STRONG SELL |
| ACIU | AC Immune SA | $299M | 10 | STRONG SELL |
| SANN.SW | Santhera Pharmaceuticals Holding AG | $290M | 24 | SELL |
| 0QNA.L | Basilea Pharmaceutica AG | $733M | 49 | HOLD |
| MOLN.SW | Molecular Partners AG | $147M | 22 | SELL |
Peer medians: ROE 12.1% · P/E 26.3x · Gross margin 55.5%